FrancophonIA/ELRC3.0 huggingface dataset:
English: In the US study the Osurnia treated dogs had a success rate of 65% which was significantly higher than the placebo treated dogs with a success rate of 44%.
Slovenian: V študiji v ZDA je bil delež uspešnosti pri psih, zdravljenih z zdravilom Osurnia, 65-odstoten, kar je bilo pomembno več kot pri psih, zdravljenih s placebom, pri katerih je bil delež uspešnosti 44-odstoten.
English: The relatively high rate of success for the placebo might have been due to the effect of cleaning the ear beforehand and because the way the product was formulated produced a protective film of gel on the surface of the ear canal.
Slovenian: Relativno velik delež uspešnosti pri placebu je bil morda posledica učinka predhodnega čiščenja ušesa, zaradi formulacije zdravila pa se je ustvarila zaščitna obloga gela na površini sluhovoda.
English: It is available as a gel to be given into the ear.
Slovenian: Na voljo je v obliki gela, ki se daje v uho.
English: Osurnia must not be used if the ear drum is perforated or in dogs with generalised demodicosis (mange caused by the mite Demodex canis).
Slovenian: Zdravilo Osurnia se ne sme uporabljati, če je bobnič predrt ali pri psih z generalizirano demodikozo (parazitsko obolenje, ki ga povzroča pršica Demodex canis).
English: Ear infections in dogs can be caused by bacteria or yeasts/fungi.
Slovenian: Ušesne infekcije pri psih lahko povzročijo bakterije ali kvasovke/glivice.
English: If the veterinary medicine is accidentally swallowed, immediate medical advice should be sought and the package leaflet or label shown to the doctor.
Slovenian: Če je prišlo do nenamernega zaužitja zdravila, je treba takoj poiskati zdravniško pomoč in zdravniku pokazati navodilo za uporabo ali nalepko.
English: Two of the active substances in Osurnia terbinafine and florfenicol, act against possible causes of infection.
Slovenian: Dve zdravilni učinkovini v zdravilu Osurnia, terbinafin in florfenikol, delujeta proti morebitnim vzrokom okužbe.
English: The third active ingredient, betamethasone acetate, is a corticosteroid, a medicine that reduces inflammation and pain.
Slovenian: Tretja zdravilna učinkovina, betametazonacetat, je kortikosteroid, zdravilo za zmanjševanje vnetja in bolečine.
English: Why has Osurnia been approved?
Slovenian: Zakaj je bilo zdravilo Osurnia odobreno?
English: Osurnia must also not be used in pregnant or breeding animals.
Slovenian: Zdravilo Osurnia se ne sme uporabljati pri brejih ali vzrejnih živalih.
English: The contents of one tube of gel are given into each infected ear.
Slovenian: V vsako okuženo uho iztisnite vsebino ene tube gela.
English: Osurnia is used to treat short lived or recurrent ear infections (otitis externa) due to Staphylococcus pseudintermedius (a bacterium) and Malassezia pachydermatitis (a yeast).
Slovenian: Zdravilo Osurnia se uporablja za zdravljenje kratkotrajnih ali ponavljajočih se ušesnih infekcij (vnetja zunanjega ušesa) zaradi Staphylococcus pseudintermedius (bakterije) in Malassezia pachydermatis (glivice).
English: In the Japanese study Osurnia was as effective as the other medicine with 78% improvement in otitis externa in both treatment groups.
Slovenian: V japonski študiji je bilo zdravilo Osurnia enako učinkovito kot primerjalno zdravilo z 78-odstotnim izboljšanjem vnetja zunanjega ušesa v obeh zdravljenih skupinah.
English: Terbinafine, florfenicol and betamethasone
Slovenian: Osurnia terbinafin/florfenikol/betametazonacetat
English: In the EU study Osurnia was as effective as the comparator medicine with both treatments resulting in 63% reduction in severity of otitis externa.
Slovenian: V študiji v EU je bilo zdravilo Osurnia enako učinkovito kot primerjalno zdravilo pri obeh zdravljenjih in je povzročilo 63-odstotno zmanjšanje resnosti vnetja zunanjega ušesa.
English: What is Osurnia used for?
Slovenian: Za kaj se zdravilo Osurnia uporablja?
English: Three field studies were conducted in dogs with otitis externa caused by bacterial or fungal infections, investigating the effect of treatment following cleaning out of the ear with saline solution; treatment with two doses of Osurnia, one week apart, was compared with another comparable ear medicine or with placebo (dummy treatment).
Slovenian: Pri psih z vnetjem zunanjega ušesa, ki ga povzročajo bakterijske ali glivične okužbe, so opravili tri terenske študije, v katerih so proučevali učinek zdravljenja po čiščenju ušesa s fiziološko raztopino; zdravljenje z dvema odmerkoma zdravila Osurnia v razmiku enega tedna so primerjali z drugim primerljivim zdravilom za zdravljenje ušesa ali placebom (zdravilom brez zdravilne učinkovine).
English: How has Osurnia been studied?
Slovenian: Kako je bilo zdravilo Osurnia raziskano?
English: The US study involved 284 dogs, 190 of which were treated with Osurnia, while 90 dogs received placebo gel (dummy treatment).
Slovenian: Študija v ZDA je vključila 284 psov, od katerih so jih 190 zdravili z zdravilom Osurnia, 90 pa jih je prejelo gel s placebom (zdravilom brez zdravilne učinkovine).
English: Osurnia is a veterinary medicine that contains three active substances: terbinafine, florfenicol and betamethasone acetate.
Slovenian: Zdravilo Osurnia je zdravilo za uporabo v veterinarski medicini, ki vsebuje tri zdravilne učinkovine: terbinafin, florfenikol in betametazonacetat.
English: The first was an EU study involving 286 dogs in which 148 dogs given Osurnia were compared with 138 dogs treated with another ear medicine containing miconazole (a medicine against fungal infections), gentamicin (an antibiotic) and hydrocortisone aceponate (a corticosteroid) for five consecutive days.
Slovenian: Prvo študijo so izvedli v EU pri 286 psih, od katerih so 148 psov, ki so prejeli zdravilo Osurnia, primerjali s 138 psi, pet dni zdravljenimi z drugim zdravilom za uho, ki vsebuje mikonazol (zdravilo proti glivičnim okužbam), gentamicin (antibiotik) in hidrokortizonaceponat (kortikosteroid).
English: The Japanese study involved 71 dogs; 49 dogs were treated with Osurnia and 22 dogs with another ear medicine containing clotrimazole (for fungal infections), gentamicin (an antibiotic) and betamethasone valerate (corticosteroid).
Slovenian: Japonska študija je vključila 71 psov, od katerih so jih 49 zdravili z zdravilom Osurnia, 22 pa z drugim zdravilom za uho, ki vsebuje klotrimazol (zdravilo proti glivičnim okužbam), gentamicin (antibiotik) in betametazonvalerat (kortikosteroid).
English: What is Osurnia?
Slovenian: Kaj je zdravilo Osurnia?
English: How does Osurnia work?
Slovenian: Kako zdravilo Osurnia deluje?
English: If accidental exposure to the eyes occurs, the eyes should be rinsed with water and in case of accidental exposure to the skin, the skin should be washed with soap and water.
Slovenian: Če zdravilo pride v stik z očmi, jih je treba sprati z vodo.
English: 4 mg (1 mg/ml) 1 vial
Slovenian: 4 mg (1 mg/ml) 1 viala
English: 4 mg (1 mg/ml) 5 vials
Slovenian: 4 mg (1 mg/ml) 5 vial
English: Immediate Packaging
Slovenian: Velikost pakirania
English: Strength Pharmaceutical Form Route of Administration
Slovenian: Farmacevtska oblika Pot uporabe Stična ovojnina Vsebina (koncentracija)
English: • The Committee considered the notification of the referral triggered by the United Kingdom under article 29(4) of Directive 2001/83/EC.
Slovenian: • Odbor je upošteval obvestilo o napotitvenem postopku, ki ga je sprožilo Združeno kraljestvo skladno s členom 29(4) Direktive 2001/83/ES.
English: Overall summary of the scientific evaluation of didanosine and associated names (see Annex I)
Slovenian: Splošni povzetek znanstvenega vrednotenja didanozina in povezanih imen (glejte Prilogo I)
English: the Netherlands and France considered that the granting of the marketing authorisation constitutes a potential serious risk to public health.
Slovenian: Nizozemska in Francija sta menili, da odobritev dovoljenja za promet z zdravilom predstavlja morebitno resno tveganje za javno zdravje;
English: However, both formulations are equivalent in terms of extent of absorption (i.e. AUC).
Slovenian: Vendar pa sta obe formulaciji enakovredni kar zadeva obseg absorpcije (tj. AUC).
English: However, the 90% CI for Cmax was 100.36132.76%.
Slovenian: Vendar je bil 90odstotni interval zaupanja za Cmax 100,36-132,76 %.
English: The only difference is the magnitude of the decrease, which is less for the test than for the reference product.
Slovenian: Edina razlika je obseg zmanjšanja, ki je manjši pri testnem kot pri referenčnem zdravilu.
English: The reference product in EU is Videx EC (200, 250 and 400 mg) hard capsules, first authorised in the United Kingdom (UK) on 19 September 2000.
Slovenian: Referenčno zdravilo v EU je Videx EC (200, 250 in 400 mg) trde kapsule, ki je bilo prvič odobreno za uporabo 19. septembra 2000 v Združenem kraljestvu.
English: The major concern raised by France and the Netherlands could not be solved during the CMD(h) referral and the issue was therefore referred to the Committee for Medicinal Products for Human Use (CHMP).
Slovenian: Glavnega pomisleka, ki sta ga izpostavili Francija in Nizozemska, med napotitvenim postopkom skupine CMD(h) ni bilo mogoče razrešiti, zato je bila zadeva posredovana Odboru za zdravila za uporabo v humani medicini (CHMP).
English: It is acknowledged that these results were outside the standard range of 80 - 125%; however these were within the wider acceptance criteria of 70 - 143% which may be used for highly variable drugs.
Slovenian: Upoštevali so, da so bili ti rezultati zunaj standardnega razpona 80-125 %; vendar so bili znotraj širših meril sprejemljivosti 70-143 %, ki se lahko uporabijo za zelo variabilna zdravila.
English: The decentralised procedure was closed on day 210, with most of the CMSs agreeing with the conclusions of the reference Member State (RMS)'s assessment report except France and the Netherlands which raised a potential serious risk to public health (PSRPH).
Slovenian: Decentralizirani postopek se je končal na 210. dan, ko je večina zadevnih držav članic soglašala z zaključki poročila o oceni referenčne države članice z izjemo Francije in Nizozemske, ki sta izrazili zaskrbljenost zaradi možnega resnega tveganja za javno zdravje (PSRPH).
English: Evaluation
Slovenian: Vrednotenje
English: The applicant provided literature references which showed that for the action of Didanosine, AUC is the most important parameter9,10,11,12,13.
Slovenian: Predlagatelj je predložil reference iz literature, ki so pokazale, da je za delovanje zdravila Didanosine najpomembnejši parameter vrednost AUC9,10,11,12,13.
English: Considering this, the sample size that may be required to meet the standard bio-equivalence criteria would be as high as 232 subjects to obtain power of at least 80%.
Slovenian: Glede na navedeno bi morala biti velikost vzorca, potrebna za izpolnjevanje standardnih meril biološke enakovrednosti, kar 232 preiskovancev, da bi dobili moč vsaj 80 %.
English: • Clinical significance of Cmax with Didanosine
Slovenian: • Klinični pomen vrednosti Cmax za zdravilo Didanosine
English: • The Committee reviewed all the data submitted by the applicant in order to support the bioequivalence between Didanosine and associated names and the reference product.
Slovenian: • Odbor je pregledal vse podatke, ki jih je predlagatelj predložil v podporo biološki enakovrednosti med zdravilom Didanosine in povezanimi imeni ter referenčnim zdravilom;
English: Irrespective of whether Didanosine is taken with or without food, the virological response is based on the total drug exposure.
Slovenian: Ne glede na to, ali se zdravilo Didanosine zaužije s hrano ali brez, virološki odziv temelji na skupni izpostavljenosti zdravilu.
English: The application for Didanosine and associated names was considered under Article 10.3 of Directive 2001/83/EC in all Concerned Members States (CMSs).
Slovenian: Vloga za zdravilo Didanosine in povezana imena je bila obravnavana v členu 10.3 Direktive 2001/83/ES v vseh zadevnih državah članicah.
English: A referral was thus triggered at the Co-ordination Group for Mutual Recognition and Decentralised ProceduresHuman (CMD(h)).
Slovenian: Napotitveni postopek je bil zato sprožen pri usklajevalni skupini za postopek z medsebojnim priznavanjem in decentralizirani postopek - zdravila za uporabo v humani medicini (CMD(h)).
English: However, the observed effect of food is lower and the Committee is of the opinion that this is not clinically relevant based on considerations relating to the mechanism of action and, in particular, that Didanosine and associated names is to be administrated on an empty stomach.
Slovenian: Vendar pa je zabeleženi vpliv hrane nižji in Odbor meni, da to ni klinično pomembno na podlagi premislekov v zvezi z mehanizmom delovanja, zlasti ker je zdravilo Didanosine in povezana imena namenjeno zaužitju na prazen želodec;
English: Schrader S et al.
Slovenian: Lopez JC et al.
English: In addition, the objecting Members States considered that the arguments provided by the applicant did not sufficiently address the consequences of the difference observed in didanosine pharmacokinetics in the fed state between test and reference products.
Slovenian: Poleg tega sta državi članici, ki sta izrazili pomisleke, menili, da argumenti, ki jih je predložil predlagatelj, niso zadostno obravnavali posledic razlik, ki so jih opazili pri farmakokinetiki didanozina pri zaužitju po obroku med testnim in referenčnim zdravilom.
English: The applicant claimed that differences in plasma concentrations of didanosine are not of clinical relevance as such since it may not result in changes in the intracellular triphosphate concentrations.
Slovenian: Predlagatelj je trdil, da razlike v koncentracijah didanozina v plazmi kot take niso klinično pomembne, saj ne povzročijo nujno sprememb znotrajceličnih koncentracij trifosfata.
English: The administration of the reference product with a high fat meal significantly decreases the AUC (19%) and Cmax (46%) of didanosine.
Slovenian: Zaužitje referenčnega zdravila z zelo mastnim obrokom močno zmanjša vrednosti AUC (19 %) in Cmax (46 %) didanozina.
English: the CHMP has recommended the granting of the marketing authorisations for which the summary of product characteristics, labelling and package leaflet remain as per the final versions achieved during the Coordination group procedure as mentioned in Annex III for Didanosine and associated names (see Annex I).
Slovenian: je odbor CHMP priporočil odobritev dovoljenja za promet z zdravilom, katerega povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo ostanejo enaki kot končne različice, pripravljene med postopkom usklajevalne skupine, kot je navedeno v Prilogi III za zdravilo Didanosine in povezana imena (glejte Prilogo I).
English: Comparison of HIV RNA suppression produced by triple regimens containing either didanosine enteric-coated or didanosine tablet formulations each administered once daily.
Slovenian: Schrader S et al. Comparison of HIV RNA suppression produced by triple regimens containing either didanosine enteric-coated or didanosine tablet formulations each administered once daily.
English: This is attributed to the delay in absorption rate of enteric coated formulation which is reflected in the Tmax which is about 2 hours for the enteric coated formulation compared to 0.67 hours for the buffered tablet.
Slovenian: To je posledica zakasnitve stopnje absorpcije enterično obložene formulacije, kar odraža Tmax, ki znaša približno 2 uri za enterično obloženo formulacijo v primerjavi z 0,67 ure za pufrano tableto.
English: Didanosine and associated names is indicated in combination with other antiretroviral drugs for the treatment of HIV-1 infected patients.
Slovenian: Didanozin in povezana imena je indiciran v kombinaciji z drugimi protiretrovirusnimi zdravili za zdravljenje bolnikov, okuženih z virusom HIV-1.
English: Therefore, it is considered that the fact that both formulations have been used for the same indications and at similar doses suggests that AUC is more relevant for ensuring efficacy of didanosine in antiviral therapy, and the changes in Cmax are unlikely to compromise antiviral efficacy.
Slovenian: Zato velja, da dejstvo, da sta bili obe formulaciji uporabljeni za enake indikacije in pri podobnih odmerkih, nakazuje, da je vrednost AUC pomembnejša za zagotovitev učinkovitosti didanozina pri protivirusni terapiji, in da spremembe vrednosti Cmax najverjetneje ne bodo poslabšale protivirusne učinkovitosti.
English: Didanosine and associated names (Gastro-resistant capsules 400 mg) was compared to the reference product Videx EC (Gastro-resistant capsules 400 mg) in 60 healthy adults under fasting conditions.
Slovenian: Zdravilo Didanosine in povezana imena (gastrorezistentne kapsule 400 mg) so primerjali z referenčnim zdravilom Videx EC (gastrorezistentne kapsule 400 mg) pri 60 zdravih odraslih pri zaužitju na tešče.
English: Since the product is to be administrated at least 2 hours before or after food intake, it is unlikely that the product ingested will be exposed to in vivo conditions, prevailing under fed state.
Slovenian: Ker je treba zdravilo vzeti vsaj 2 uri pred obrokom oz. 2 uri po njem, je malo verjetno, da bo zaužito zdravilo izpostavljeno pogojem in-vivo, ki prevladujejo pri zaužitju po obroku.
English: Both studies were carried out using open label, randomised, two treatment, two sequence, two period, single dose cross-over design.
Slovenian: Obe študiji sta bili izvedeni z odprto, randomizirano, enoodmerno navzkrižno zasnovo z dvema oblikama zdravljenja, dvema zaporedjema in dvema fazama.
English: During the decentralised procedure France and the Netherlands expressed the opinion that bioequivalence had not been demonstrated in the fed conditions as Cmax was outside the 80-125% acceptability limits1.
Slovenian: Med decentraliziranim postopkom sta Francija in Nizozemska izrazili mnenje, da biološka enakovrednost ni bila dokazana pri zaužitju po obroku, saj je bila vrednost Cmax zunaj meja sprejemljivosti 80−125 %1.
English: Didanosine (2', 3'-dideoxyinosine) is an inhibitor of the in vitro replication of human immunodeficiency virus (HIV) in cultured human cells and cell lines.
Slovenian: Didanozin (2', 3'-dideoksinozin) je zaviralec in vitro replikacije virusa humane imunske pomanjkljivosti (HIV) v gojenih človeških celicah in celičnih linijah.
English: • The Committee noted that in the fed study, both formulations were subject to a food effect reducing plasma concentrations.
Slovenian: • Odbor je zabeležil, da se je v študiji pri zaužitju po obroku pri obeh formulacijah pojavilo zmanjšanje koncentracij v plazmi zaradi hrane.
English: The Applicant claimed that the significant decrease observed under fed conditions for Cmax for the test product (90% CI outside the standard range) may be attributed to high inter-individual variability with respect to Cmax which was 36% in the study conducted under fed conditions.
Slovenian: Predlagatelj je trdil, da je pomembno zmanjšanje vrednosti Cmax, ki so ga opazili pri zaužitju po obroku za testno zdravilo (90-odstotni interval zaupanja zunaj standardnega razpona), mogoče pripisati visoki interindividualni variabilnosti glede Cmax, ki je bila v študiji, izvedeni pri zaužitju po obroku, 36 %.
English: This observation is in line with the results presented in the current application where AUC and Cmax of the test product significantly decrease under fed conditions.
Slovenian: Ta ugotovitev je v skladu z rezultati, predstavljenimi v trenutni vlogi, kjer se vrednosti AUC in Cmax testnega zdravila močno zmanjšata pri zaužitju po obroku.
English: The main purpose of conducting bioequivalence fed study is to exclude food related effects, such as dose-dumping (in particular for gastro-resistant formulations) or failure of protection from acid mediated degradation in the stomach.
Slovenian: Glavni namen izvajanja študije biološke enakovrednosti pri zaužitju po obroku je izločiti vplive, povezane s hrano, kot so sprostitev celotnega odmerka naenkrat (zlasti za gastrorezistentne formulacije) ali odpoved zaščite pred s kislino povzročeno degradacijo v želodcu.
English: Of note, bioequivalence in fasted state is considered to be the most important as this product is intended to be taken on an empty stomach.
Slovenian: Upoštevati je treba še, da kot najpomembnejša šteje biološka enakovrednost pri zaužitju na tešče, saj je to zdravilo namenjeno zaužitju na prazen želodec.
English: • Observed food effect for test and reference products As per the current recommendations for modified release formulations1,2, bioequivalence studies in fasted and fed conditions are required.
Slovenian: • Opažen vpliv hrane na testno in referenčno zdravilo V skladu s trenutnimi priporočili za formulacije s prirejenim sproščanjem 1,2 je treba predložiti študije biološke enakovrednosti pri zaužitju na tešče in po obroku.
English: In order to demonstrate the safety and efficacy of Didanosine and associated names in combination with other antiretroviral drugs in the treatment of HIV-1 infected patients, the application dossier was based on two single dose bioequivalence studies, one under fasting state and one under fed state.
Slovenian: Da bi dokazali varnost in učinkovitost zdravila Didanosine in povezanih imen v kombinaciji z drugimi protiretrovirusnimi zdravili pri zdravljenju bolnikov, okuženih z virusom HIV-1, je dokumentacija vloge temeljila na dveh enoodmernih študijah biološke enakovrednosti, eno pri zaužitju na tešče in drugo pri zaužitju po obroku.
English: The pharmacokinetics data reveals that the plasma concentration (Cmax) obtained from enteric-coated capsule formulation of didanosine is about 40% lower as compared to the buffered tablet formulation.
Slovenian: Farmakokinetični podatki kažejo, da so koncentracije v plazmi (Cmax), pridobljene iz didanozina v obliki enterično obložene kapsule, približno 40 % nižje v primerjavi z didanozinom v obliki pufrane tablete.
English: The Committee acknowledged that the conventional criterion for bioequivalence for maximum plasma concentration (Cmax) was outside the 80-125% acceptability limits.
Slovenian: Odbor je upošteval, da je bilo konvencionalno merilo biološke enakovrednosti za največjo koncentracijo v plazmi (Cmax) zunaj meja sprejemljivosti 80−125 %.
English: • The Committee is of the opinion that bioequivalence has been demonstrated under fasting conditions which is the recommended state for administration of didanosine.
Slovenian: • Odbor meni, da je bila biološka enakovrednost dokazana pri zaužitju na tešče, kar se tudi priporoča za zaužite didanozina;
English: 1 Note for Guidance on the investigation of bioavailability and bioequivalence (EMA/CPMP/EWP/QWP/1401/98) 2 Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms
Slovenian: 1 Navodila o raziskovanju biološke razpoložljivosti in biološke enakovrednosti (EMA/CPMP/EWP/QWP/1401/98) 2 Navodila o farmakokinetičnem in kliničnem vrednotenju formulacij odmerkov s prirejenim sproščanjem (EMA/CPMP/EWP/280/96/Corr1)
English: Pharmacokinetics studies conducted on Didanosine formulations reveal that administration of the product with food or immediately after food results in decreased in vivo availability of the drug.
Slovenian: V farmakokinetičnih študijah formulacij zdravila Didanosine so ugotovili, da zaužitje zdravila s hrano ali takoj po obroku zmanjša in-vivo razpoložljivost zdravila.
English: didanosine in treatment of HIV infecting were conducted using buffered tablets3,4,5,6,7,8.
Slovenian: V začetnih kliničnih preskušanjih za dokaz učinkovitosti didanozina pri zdravljenju bolnikov, okuženih z virusom HIV, so uporabljali pufrane tablete3,4,5,6,7,8.
English: Didanosine has to be first converted intracellularly to its active metabolite ddATP (responsible for antiviral activity) which has a significantly longer intracellular half-life (about 43 hours) as compared with plasma half-life of didanosine.
Slovenian: Didanozin se mora najprej pretvoriti znotrajcelično v aktivni presnovek ddATP (odgovoren za protivirusno aktivnost), ki ima veliko daljši znotrajcelični razpolovni čas (približno 43 ur) od razpolovnega časa didanozina v plazmi.